Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review (Q38085657)

28 August 2017

Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review (English)

1 reference

28 August 2017

1 reference

J Vora

1

1 reference

PubMed ID

23451796

28 August 2017

T Heise

series ordinal

2

1 reference

28 August 2017

24 March 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

701-712

1 reference

28 August 2017

8

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

28 August 2017

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Type 1 diabetes among adolescents: reduced diabetes self-care caused by social fear and fear of hypoglycemia.

21 January 2018

1 reference

Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature

21 January 2018

1 reference

Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups

21 January 2018

1 reference

Postprandial glucose regulation: new data and new implications

21 January 2018

1 reference

Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?

21 January 2018

1 reference

Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

21 January 2018

1 reference

Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients

21 January 2018

1 reference

'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting

21 January 2018

1 reference

Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

21 January 2018

1 reference

Glucose variability; does it matter?

21 January 2018

1 reference

Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes

21 January 2018

1 reference

A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study

21 January 2018

1 reference

For debate. Glucose variability and diabetes complication risk: we need to know the answer

21 January 2018

1 reference

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence

21 January 2018

1 reference

Severe hypoglycemia predicts mortality in diabetes

21 January 2018

1 reference

Hypoglycemia and cardiovascular risks

21 January 2018

1 reference

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus

21 January 2018

1 reference

Prediction of severe hypoglycemia

21 January 2018

1 reference

Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?

21 January 2018

1 reference

Postprandial hyperglycemia and glycemic variability: should we care?

21 January 2018

1 reference

Impaired glucose tolerance.

21 January 2018

1 reference

Insulin binding in diabetes. Relationships with plasma insulin levels and insulin sensitivity

21 January 2018

1 reference

Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes

21 January 2018

1 reference

Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin

21 January 2018

1 reference

Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes

21 January 2018

1 reference

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

21 January 2018

1 reference

Refining basal insulin therapy: what have we learned in the age of analogues?

21 January 2018

1 reference

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

21 January 2018

1 reference

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

21 January 2018

1 reference

Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures.

21 January 2018

1 reference

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir wit

21 January 2018

1 reference

Variability of insulin absorption and insulin action

21 January 2018

1 reference

Limitations to subcutaneous insulin administration in type 1 diabetes

21 January 2018

1 reference

Reproducibility and variability in the action of injected insulin

21 January 2018

1 reference

A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine

21 January 2018

1 reference

Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion

21 January 2018

1 reference

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

21 January 2018

1 reference

Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients.

21 January 2018

1 reference

Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine.

21 January 2018

1 reference

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial

21 January 2018

1 reference

Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure.

21 January 2018

1 reference

Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years

21 January 2018

1 reference

In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.

21 January 2018

1 reference

A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS.

21 January 2018

1 reference

Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus

21 January 2018

1 reference

Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

21 January 2018

1 reference

Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy

21 January 2018

1 reference

Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.

21 January 2018

1 reference

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

21 January 2018

1 reference

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12087

1 reference

28 August 2017

1 reference

PubMed ID

23451796